BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, September 7, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» ACR-246 demonstrates best-in-class 5T4-targeting ADC properties in preclinical solid tumor models
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
ACR-246 demonstrates best-in-class 5T4-targeting ADC properties in preclinical solid tumor models
June 5, 2024
No Comments
Hangzhou Adcoris BioPharma Co. Ltd. is developing ACR-246, a novel 5T4-targeted antibody-drug-conjugate (ADC), for the treatment of solid tumors.
BioWorld Science
Conferences
American Society of Clinical Oncology
Cancer
Antibody-drug conjugate
Immuno-oncology